Chinese censors today deleted articles and postings about the vaccine industry as an online outcry over the country's latest vaccine scandal intensified.
Regulators said last week that they had halted production of a rabies vaccine at a large pharmaceutical company in the northeast after finding fabricated records and other problems during an inspection.
It was just the latest in a series of health and safety scandals which have fuelled fear over the safety of basic food and medicine and anger at regulators asleep on the job.
China's censors and regulators struggled to stay abreast of the public's response, deleting posts on WeChat as state media tried to take control of the narrative.
On Sunday night China's Food and Drug Administration (CFDA) announced it had ordered all production stopped at the vaccine maker and launched an investigation.
Changchun Changsheng Biotechnology is China's second largest maker of the rabies vaccine and a subsidiary of a large publicly-traded vaccine maker.
Anxiety grew over the weekend as an essay alleging corruption and murky practices in the vaccine industry spread across WeChat. Netizens reposted the self-published essay as censors swooped in to delete the content.
The CFDA said last week that the problematic rabies vaccine had not left Changsheng's factory.
The company said in a stock exchange filing Sunday that it had already halted production of another vaccine -- for diphtheria, tetanus and pertussis -- which regulators found last year to be sub-standard and which had also become the focus of public attention.
Still the action aroused concern that other problematic vaccines had already been administered to children. In Beijing, an unnamed official at the Center for Disease Control and Prevention told local website The Paper that parents in China's capital need not worry: "Beijing does not have either of these two vaccines in question, the public can be at ease."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories
Over 30 subscriber-only stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app